ObsEva SA, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for women suffering from reproductive health and pregnancy disorders. It is developing OBE2109, an oral gonadotropin-releasing hormone receptor antagonist for the treatment of pain associated with endometriosis and heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women; nolasiban, an oral oxytocin receptor antagonist to enhance clinical pregnancy and live birth rates in women undergoing in vitro fertilization; and OBE022, an oral and selective prostaglandin F2a, or PGF2a receptor antagonist, as a once daily treatment for preterm labor in weeks 24 to 34 of gestational age. The company was founded in 2012 and is headquartered in Plan-les-Ouates, Switzerland.
Industry, Sector and Symbol
Industry N/A
Sub-IndustryN/A
SectorMedical
Phone41-22-552-3840
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
EmployeesN/A
Next Earnings DateN/A
OptionableNot Optionable
Obseva (NASDAQ:OBSV) Frequently Asked Questions
What is Obseva's stock symbol?
Obseva trades on the NASDAQ under the ticker symbol "OBSV."
How were Obseva's earnings last quarter?
Obseva SA (NASDAQ:OBSV) posted its earnings results on Tuesday, March, 5th. The company reported ($0.46) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.47) by $0.01. View Obseva's Earnings History.
What price target have analysts set for OBSV?
6 equities research analysts have issued 12-month target prices for Obseva's stock. Their predictions range from $24.00 to $44.00. On average, they anticipate Obseva's stock price to reach $31.1667 in the next year. This suggests a possible upside of 141.8% from the stock's current price. View Analyst Price Targets for Obseva.
What is the consensus analysts' recommendation for Obseva?
6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Obseva in the last year. There are currently 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Obseva.
What are Wall Street analysts saying about Obseva stock?
Here are some recent quotes from research analysts about Obseva stock:
- 1. According to Zacks Investment Research, "ObsEva SA is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of novel therapeutics for woman's reproductive health and pregnancy. ObsEva SA is headquartered in Geneva, Switzerland. " (3/6/2019)
- 2. HC Wainwright analysts commented, "Valuation methodology, risks and uncertainties. Our risk-adjusted net present value (rNPV) approach ascribes $1.83B to linzagolix (formerly to nolasiban. We utilize an 85% probability of approval for linzagolix and 75% for nolasiban. The current total valuation of $2.2B translates to $44.00 per share, assuming roughly 49M fully-diluted shares outstanding as of end-2019. The fully-diluted shares projected in 12 months includes the exercise of all remaining outstanding options, as well as an equity financing involving the sale of roughly 2M shares in 1H19." (12/10/2018)
Has Obseva been receiving favorable news coverage?
News articles about OBSV stock have been trending somewhat positive this week, InfoTrie Sentiment Analysis reports. The research group identifies positive and negative news coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Obseva earned a media sentiment score of 1.1 on InfoTrie's scale. They also gave media coverage about the company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an effect on the stock's share price in the next several days.
Who are some of Obseva's key competitors?
Some companies that are related to Obseva include Halozyme Therapeutics (HALO), Mediclinic International (MDC), Denali Therapeutics (DNLI), Insmed (INSM), BioTelemetry (BEAT), Arena Pharmaceuticals (ARNA), Portola Pharmaceuticals (PTLA), CONMED (CNMD), Irhythm Technologies (IRTC), AMN Healthcare Services (AMN), Zogenix (ZGNX), Biohaven Pharmaceutical (BHVN), USANA Health Sciences (USNA), Aerie Pharmaceuticals (AERI) and Regenxbio (RGNX).
What other stocks do shareholders of Obseva own?
Who are Obseva's key executives?
Obseva's management team includes the folowing people:
- Dr. Ernest Loumaye, Co-Founder, CEO & Director (Age 67)
- Mr. Timothy M. Adams, Chief Financial Officer (Age 59)
- Dr. Jean-Pierre Gotteland Ph.D., Chief Scientific Officer and Head of R&D (Age 54)
- Mr. Mario Vincent Corso, Sr. Director of Investor Relations
- Dr. Elke Bestel, Chief Medical Officer & Head of Pharmacovigilance (Age 53)
When did Obseva IPO?
(OBSV) raised $98 million in an initial public offering (IPO) on Thursday, January 26th 2017. The company issued 6,500,000 shares at a price of $14.00-$16.00 per share. Credit Suisse, Jefferies and Leerink Partners served as the underwriters for the IPO.
Who are Obseva's major shareholders?
Obseva's stock is owned by a number of of retail and institutional investors. Top institutional investors include First Manhattan Co. (5.81%), Aisling Capital Management LP (3.80%), Polar Capital LLP (0.48%), Dimensional Fund Advisors LP (0.19%), Dimensional Fund Advisors LP (0.19%) and United Services Automobile Association (0.07%).
Which major investors are selling Obseva stock?
OBSV stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC.
Which major investors are buying Obseva stock?
OBSV stock was acquired by a variety of institutional investors in the last quarter, including Aisling Capital Management LP, First Manhattan Co., Dimensional Fund Advisors LP, Dimensional Fund Advisors LP, Polar Capital LLP, Wedbush Securities Inc., Jane Street Group LLC and United Services Automobile Association.
How do I buy shares of Obseva?
Shares of OBSV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Obseva's stock price today?
One share of OBSV stock can currently be purchased for approximately $12.89.
How big of a company is Obseva?
Obseva has a market capitalization of $586.20 million. The company earns $-76,720,000.00 in net income (profit) each year or ($2.25) on an earnings per share basis.
What is Obseva's official website?
How can I contact Obseva?
Obseva's mailing address is Chemin des Aulx 12 Plan-les-Ouates, Geneva V8, 1228. The company can be reached via phone at 41-22-552-3840 or via email at [email protected]
MarketBeat Community Rating for Obseva (NASDAQ OBSV)
MarketBeat's community ratings are surveys of what our community members think about Obseva and other stocks. Vote "Outperform" if you believe OBSV will outperform the S&P 500 over the long term. Vote "Underperform" if you believe OBSV will underperform the S&P 500 over the long term. You may vote once every thirty days.
